“Overall, we continue to expect Surgical to return to more normalized growth starting next quarter as these comparisons ease.”

In context

“ate their imaging technologies for spine care. We expect CST to continue to deliver sustained above-market growth with AiBLE and its differentiated best-in-class solutions, attracting not only spine surgeons around the world, but also the best sales reps and distributors who continue to leave the competition to join our winning team. Next, in Surgical, we had flat results. As I mentioned last quarter, we had difficult year-over-year comparisons given the supply recovery last year as well as the Korean market slowdown from the ongoing physician strikes. It's worth noting that on a sequential basis, Surgical had strong high single-digit growth, both globally and in the U.S. We had outsized strength in advanced energy, driven by accelerated adoption of our LigaSure XP Maryland vessel sealer. Overall, we continue to expect Surgical to return to more normalized growth starting next quarter as these comparisons ease. In Cardiac Rhythm Management, we had another strong quarter, growing in the mid-single digits, including high single-digit growth in both defibrillation solutions and in cardiac pacing therapies. Our Micra leadless pacemaker franchise, grew high-teens with broad strength around the world. Now turning to our synergistic businesses, which collectively grew mid-single digits and represented over 30% of our revenue. The highlight again this quarter was Neuromodulation, where growth accelerated to 12% and the business continues to grow well above the market. We're seeing broad-based growth across product lines, including Pain Stim and Brain Modulation. In Pain Stim, we grew 10%, including 12% growth in the U.S. on the continued launch of the Inceptiv closed-loop spinal cord stimulator. The inn”